[Antiretroviral drugs in severe acute respiratory syndrome]

Details

Serval ID
serval:BIB_FDB41EBAFF0F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
[Antiretroviral drugs in severe acute respiratory syndrome]
Journal
Presse Med
Author(s)
Yazdanpanah Y., Guery B.
ISSN
0755-4982 (Print)
ISSN-L
0755-4982
Publication state
Published
Issued date
01/2006
Volume
35
Number
1 Pt 2
Pages
105-7
Language
french
Notes
Yazdanpanah, Yazdan
Guery, Benoit
fre
English Abstract
Review
France
Presse Med. 2006 Jan;35(1 Pt 2):105-7. doi: 10.1016/s0755-4982(06)74531-6.
Abstract
Inhibition of viral assembly (protease inhibitors) and of fusion of viral and target membranes (fusion inhibitors) are general approaches to antiviral treatment, not specific for HIV. Nonetheless, the agents that induce these phenomena are most often specific for a given virus or virus family. Drugs developed for HIV treatment were reevaluated for use against severe acute respiratory syndrome-coronavirus (SARS-CoV) during and after the epidemic in 2003, in view of the absence of any other available treatment. Of the protease and entry inhibitors approved for treating HIV-infected patients, none was effective against SARS-CoV, although in vitro activity against this virus was reported for the protease inhibitor lopinavir/ritonavir, in results that have not been confirmed in the most recent studies. The epidemiologic methods used to assess this drug's efficacy are not robust. Preliminary results for SARS treatment with protease and entry inhibitors, although at early stages of development, are promising.
Keywords
Anti-HIV Agents/therapeutic use, Anti-Retroviral Agents/administration & dosage/*therapeutic use, Antiviral Agents/administration & dosage/*therapeutic use, Clinical Trials as Topic, Cohort Studies, Drug Therapy, Combination, HIV Infections/drug therapy, Humans, Lopinavir, Protease Inhibitors/administration & dosage/pharmacology/*therapeutic use, Pyrimidinones/administration & dosage/pharmacology/*therapeutic use, Ribavirin/administration & dosage/*therapeutic use, Ritonavir/administration & dosage/pharmacology/*therapeutic use, SARS Virus/*drug effects, Severe Acute Respiratory Syndrome/*drug therapy/prevention & control/virology, Viral Fusion Proteins/antagonists & inhibitors
Pubmed
Create date
29/04/2021 10:59
Last modification date
30/04/2021 6:38
Usage data